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Abstract: Lixisenatide is a once-daily glucagon-like peptide 1 (GLP-1) receptor agonist 
mimicking several favorable actions of endogenous GLP-1 that result in improved glycemic 
control with little or no hypoglycemia and weight loss. Phase II trials have shown that lixisenatide 
20 µg once daily restores first-phase insulin release in patients with type 2 diabetes and improves 
the second-phase insulin response. Administered once or twice daily for 4 weeks, it significantly 
reduced postprandial and fasting blood glucose levels, and glycosylated hemoglobin (HbA
1c
). 
The efficacy and safety of lixisenatide once daily is being assessed in the GETGOAL Phase III 
clinical trial program. Results have shown beneficial effects on HbA
1c
 compared with placebo in 
combination with commonly used antidiabetes agents, with no increased risk of hypoglycemia 
and with beneficial weight reduction. Adverse effects were similar to those observed for available 
GLP-1 receptor agonists, the most frequent being gastrointestinal. Both GLP-1 receptor agonists 
and long-acting insulin analogs have demonstrated protective effects on beta cells in preclinical 
studies. This, along with the pronounced effect of lixisenatide on postprandial plasma glucose, 
provides a rationale for combining it with long-acting basal insulin analogs, in the hope that the 
additive effects on glycemic control combined with a potential benefit on islet cells may lead to 
a new treatment approach to control blood glucose better and prevent long-term complications 
in patients with type 2 diabetes.
Keywords: GLP-1 receptor agonist, combination therapy, GETGOAL program, insulin, 
 lixisenatide, postprandial plasma glucose, type 2 diabetes
Core Evidence clinical impact summary for lixisenatide in type 2 diabetes
Outcome measure Evidence Implications
Disease-oriented  
evidence
Demonstrates all the beneficial  
effects associated with  
glucagon-like peptide 1  
receptor agonists: improved  
glycemic control, increased meal-
related and glucose-stimulated 
insulin secretion, suppression of 
glucagon, weight loss, delayed 
gastric emptying, appetite 
suppression, and enhanced  
beta cell function
Provides another 
therapeutic choice  
for a large patient  
population
Lixisenatide has a pronounced  
effect on postprandial  
plasma glucose levels
Provides a rationale for 
combining with long-
acting insulin analogs 
for additive effects on 
glycemic control
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Introduction
Worldwide, the type 2 diabetes epidemic continues to expand 
and exert socioeconomic strain on national health care systems.1 
Statistics from the UK indicate that around 10% of National 
Health Service spending is on diabetes and its complications, 
which equates to £9 billion.2 Although there is a wide variation 
in prevalence by European country, the total number of adults 
with diabetes in the region was predicted to reach 55.2 million 
by 2010, accounting for 8.5% of the adult population.3
In the UK, as in other countries, the prevalence of type 2 
diabetes is increasing and varies with factors including age, 
ethnic group, and social deprivation. Quality and Outcomes 
Framework data, which provide information on people 
17 years of age and older with type 2 diabetes registered 
with general practices, indicate that during the period April 
2009 to March 2010, the number of people diagnosed in 
England increased by more than 125,000 on the previous 
year, resulting in a UK prevalence of 5.4%.4 The true 
prevalence will be far higher than this because this figure 
does not include the estimated 1.1 million people in the UK 
with undiagnosed type 2  diabetes. These disturbing figures 
illustrate the importance of preventing type 2 diabetes, and 
helping those who do have the disease to manage it to prevent 
serious complications, such as renal failure, diabetic retin-
opathy, amputation, and cardiovascular disease.
The past decade has seen considerable progress in our 
understanding of the pathogenetic mechanisms involved 
in the progression of the disease. The treatment of type 2 
diabetes has taken advantage of these scientific advances 
and resulted in several new therapies coming to the market. 
Some of the most important developments in this area sur-
round glucagon-like peptide 1 (GLP-1), a naturally occur-
ring peptide that is released from the gut within minutes 
of eating a meal.5 GLP-1 possesses a number of properties 
that make it a potentially ideal antidiabetes agent, including 
glucose-dependent insulin secretion, inhibition of glucagon 
secretion, delayed gastric emptying, and promotion of satiety. 
In addition, direct effects on beta-cell growth and survival 
have been identified.5
Two therapeutic strategies have been developed to take 
advantage of these actions. The first is to use GLP-1  receptor 
agonists, which have a substantially longer half-life than GLP-1 
due to reduced degradation by the dipeptidyl peptidase 4 (DPP-4) 
enzyme. Exenatide and liraglutide are the two currently avail-
able GLP-1 receptor agonists. The second strategy is to inhibit 
DPP-4, which prolongs the half-life of endogenously released 
GLP-1 and has led to the development of the DPP-4 inhibitors. 
Both strategies have proved very successful and the use of these 
agents as add-on treatment for type 2 diabetes is endorsed by 
the National Institute for Health and Clinical Excellence,6 
the European Association for the Study of Diabetes,7 and the 
American Diabetes Association,8 among others.
GLP-1 also has a number of favorable effects for patients 
with type 2 diabetes beyond its benefits on glucose control. 
For example, agents that activate the GLP-1 receptor improve 
glucose tolerance alongside a low risk of hypoglycemia, 
beneficial weight loss, and have the potential to modify disease 
progression.5 The diverse actions of this class, and their novel 
and complementary mechanism of action, make them an 
appealing addition to the current therapeutic options for treating 
type 2 diabetes and significant research is ongoing in this field. 
The latest agent to reach Phase III clinical trials is the GLP-1 
receptor agonist, lixisenatide. To provide the most up to date 
information on this agent, the Clinicaltrials.gov registry was first 
searched to identify all relevant clinical trials, then conference 
abstracts, and Medline were searched to obtain all published 
articles. This review summarizes all the available published 
evidence for lixisenatide up to the end of June 2011.
Lixisenatide: a new GLP-1 receptor 
agonist
The very short half-life of endogenous GLP-19 has 
led to extensive research to find new compounds with 
pharmacokinetic properties suitable for development of a 
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Outcome measure Evidence Implications
Patient-oriented evidence
Hypoglycemia Low risk of hypoglycemia in 
combination with insulin
if approved, lixisenatide may 
offer an alternative in patients 
in whom hypoglycemia must 
be avoided or weight loss is 
important
Gastrointestinal adverse events Nausea is the most frequent 
adverse event similar to 
other glucagon-like peptide 1 
receptor agonists
weight loss Beneficial weight loss has been 
observed with lixisenatide
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pharmaceutical agent. Exendin-4 was first isolated from the 
salivary gland of the Gila monster (Heloderma suspectum), 
and characterization showed that the peptide was structurally 
related to but distinct from GLP-1, with a sequence homology 
of 53%.9 Exendin-4 is a potent agonist for the mammalian 
GLP-1 receptor with a longer in vivo half-life, prolonged 
duration of action, and GLP-mimetic actions.
Lixisenatide (also known as AVE0010 and ZP10) is a 
GLP-1 receptor agonist in late-stage development. In 2003, 
Zealand Pharma outlicensed lixisenatide to Sanofi-Aventis 
who is now responsible for all further clinical  development. 
Like exenatide, lixisenatide is a synthetic version of 
exendin−4. It is able to withstand physiological degradation 
by DPP-4 as a result of C-terminal modification with six lysine 
residues and deletion of one proline (Figure 1). The half-life 
of lixisenatide is 2−4 hours, and it is classed as a short-acting 
GLP-1-receptor agonist, compared with the long-acting 
GLP-1-based peptides, liraglutide and  albiglutide. Despite its 
relatively short half-life, lixisenatide is intended for once-daily 
dosing as a result of its strong binding affinity to the GLP-1 
receptor. Receptor binding studies have shown that the median 
inhibitory concentration (IC
50
) of lixisenatide for the human 
GLP-1 receptor is 1.4 nM, which is approximately four-fold 
greater than the affinity of GLP-1.10 In contrast, liraglutide 
has been shown to displace radiolabeled GLP-1 from human 
GLP-1 receptors with an IC
50
 of 0.11 nM, compared with 
values of 0.35 nM for GLP-1 and 0.55 nM for exenatide.
Preclinical findings
The preclinical pharmacological profile of lixisenatide 
demonstrates a number of important acute and longer-term 
actions that are highly relevant to the maintenance of glucose 
homeostasis. A detailed review of the preclinical pharmaco-
logical profile of lixisenatide is provided by Werner et al11 
and is only briefly summarized here.
Effects on glucose-stimulated insulin 
secretion
The beneficial effects of lixisenatide on glycemic control 
have been demonstrated in both healthy animals and in 
animal models of type 2 diabetes. In isolated pancreas from 
healthy Wistar rats, lixisenatide significantly improved 
glucose-stimulated insulin secretion compared with saline 
control after a switch to high glucose concentrations. The 
effect of lixisenatide on insulin secretion was greater than 
that observed with GLP-1, consistent with the greater affinity 
reported for lixisenatide at the GLP-1 receptor.12
When fed a lipid-rich diet, the inherited obesity gene 
mutation of the Zucker Diabetic Fatty (ZDF) rat provides us 
with an animal model that mimics human adult onset type 
2 diabetes and its related complications. A continuous sub-
cutaneous infusion of lixisenatide 50 µg/kg/day for 6 weeks 
to ZDF rats preserved both first-phase and second-phase 
glucose-stimulated insulin secretion and total insulin secre-
tion, whereas untreated rats showed a progressive impairment 
of insulin secretion and loss of the biphasic pattern of insulin 
secretion during the development of type 2 diabetes.12 Treated 
ZDF rats also demonstrated a suppression of glucagon secre-
tion in response to high glucose concentrations.
Effects on blood glucose levels
In healthy normoglycemic dogs, single subcutaneous  injections 
of lixisenatide produced dose-dependent reductions in plasma 
glucose after an oral glucose challenge and significantly 
reduced postprandial glucose excursions by 67% compared 
with placebo without increasing insulin  concentrations.13 
Using absorption of paracetamol as a measure of gastric 
emptying, the researchers observed that lixisenatide signifi-
cantly reduced arterial plasma paracetamol concentration by 
53% versus placebo, suggesting that the effect of lixisenatide 
on postprandial blood glucose  excursions in dogs is, at least 
in part, related to inhibition of gastric emptying and delayed 
intestinal glucose absorption.13
Dose-dependent reductions in plasma glucose after an 
oral glucose challenge have been demonstrated in both the 
db/db mouse and ZDF rat,10,14 two rodent models of diabetes 
in which mutations in the leptin receptor gene result in 
obesity and insulin resistance. Importantly, this activity was 
glucose-dependent with no effect at physiological glucose 
concentrations. Although the lack of effective leptin signaling 
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GLP-1 (7–36) amide
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Figure 1 Structure of lixisenatide. The amino acid sequence of lixisenatide is shown alongside that of exendin-4 and pharmacologically active forms of human glucagon-like 
peptide 1. Amino acids highlighted in black show elements of lixisenatide or exendin-4 that differ from human glucagon-like peptide 1. Amino acids highlighted in gray show 
elements unique to lixisenatide.11
Abbreviation: GLP-1, glucagon-like peptide 1.
Note: Reprinted from Regulatory Peptides, Vol 164, U Werner, H Haschke, AW Herling, W Kramer, Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist 
for the treatment of type 2 diabetes, Pages 58–64, Copyright 2010, with permission from Elsevier.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
69
Lixisenatide in type 2 diabetes
Core Evidence 2011:6
in db/db mice and ZDF rats promotes the development of 
diabetes via mechanisms that do not commonly occur in most 
human patients with type 2 diabetes, these animal models 
have contributed substantially to our understanding of the 
pathophysiology and treatment of type 2 diabetes and its com-
plications. In db/db mice, chronic lixisenatide administration 
prevented the progressive deterioration in glucose tolerance 
observed in control animals and was associated with signifi-
cant dose-dependent reductions in glycosylated hemoglobin 
(HbA
1c
).10 In ZDF rats, a continuous subcutaneous infusion 
of lixisenatide 50 µg/kg/day for 12 weeks significantly 
decreased basal blood glucose and improved oral glucose 
tolerance compared with control animals.14 At the end of the 
study, there was also a significant 1.7% reduction in HbA
1c
 
compared with controls. Lixisenatide had no hypoglycemic 
effect and did not change HbA
1c
 in normoglycemic rats.
Effects on beta cell function
There is also evidence from animal studies that lixisenatide 
can maintain beta cell mass and function through stimulation 
of islet cell proliferation and neogenesis, and inhibition of 
islet cell apoptosis. In two experiments in the db/db mouse 
model of diabetes in which animals were treated chroni-
cally with intraperitoneal administration of lixisenatide up 
to 500 µg/kg or control, lixisenatide preserved pancreatic 
insulin mRNA expression and was associated with a dose-
dependent increase in beta cell mass.10
The effects of lixisenatide on beta cell function have also 
been evaluated using pancreatic islets isolated from eight post 
mortem subjects who did not have type 2 diabetes.15 The islets 
were cultured either acutely (1 hour) under  physiological 
conditions at low (2.8 mmol/L) or high (20 mmol/L) 
glucose concentrations, or chronically (48 hours) under 
 lipotoxic conditions, followed by a 1-hour incubation at 
low or high glucose concentrations. Under physiological 
conditions, lixisenatide dose-dependently increased glucose-
stimulated insulin secretion in human islets to a greater 
degree than GLP-1. Chronic lipotoxic stress conditions led 
to increases in triglyceride content, decreases in insulin con-
tent, and reductions in glucose-stimulated insulin secretion 
in untreated human islets. Although lixisenatide and GLP-1 
had no effect on triglyceride content, both peptides were 
able to prevent lipid-induced insulin depletion. Moreover, 
lixisenatide and GLP-1 were able to preserve the beta-cell 
response to glucose in human islets.
In vitro studies using the INS-1 rat pancreatic beta cell 
line have shown that lixisenatide protects beta cells against 
lipid-induced and cytokine-induced apoptosis in the order 
of 50%−60%.16 Similar findings have been observed when 
beta cells are pretreated with several different rapid-acting 
or long-acting insulin analogs, and combined treatment of 
cells with lixisenatide and the long-acting analog, insulin 
glargine, has revealed additive activity and the prevention of 
both cytokine-induced and free fatty acid-induced apoptosis 
by up to 80%. These early findings are now being evaluated 
in clinical trials to determine whether the combination of 
a GLP-1 receptor agonist, such as lixisenatide, and insulin 
glargine might represent an effective strategy for preserving 
beta cell mass in patients with type 2 diabetes.
Pharmacokinetic and 
pharmacodynamic studies
Two lixisenatide trials have determined the dose-response 
effect and successfully demonstrated the restoration of insulin 
release in patients with type 2 diabetes taking oral anti-
diabetes agents.17,18 In a 4-week study, the pharmacokinetics 
and pharmacodynamics of stepwise increasing doses of lix-
isenatide were examined in 64 patients with type 2 diabetes 
(HbA
1c
 $ 7.0% to # 10.0%).17 Patients were randomized to 
one of three treatment arms, ie, lixisenatide once daily (5 µg 
in the morning with volume-matched placebo in the evening), 
lixisenatide twice daily (5 µg in the morning and 5 µg in the 
evening), or volume-matched placebo in the morning and 
evening. The lixisenatide treatment was increased, based 
on tolerability, every fifth day in increments of 2.5 µg to a 
maximum dose of 20 µg per injection (ie, 20 µg in the once-
daily arm and 40 µg in the twice-daily arm). Patients were 
on a stable treatment with metformin and/or sulfonylurea, 
which was maintained throughout the study.
Lixisenatide concentrations increased in a dose- dependent 
manner, reaching peak concentrations between one and two 
hours (Table 1).17 At each dose level (5 µg, 10 µg, and 20 µg) 
the morning steady-state plasma concentration profiles were 
similar for the once-daily and twice-daily lixisenatide treatment 
groups. Mean area under the concentration-time curve (AUC) 
and peak plasma concentration (C
max
) increased according to the 
dose and dose frequency of lixisenatide (Table 1). Comparisons 
of lixisenatide doses (5 µg, 10 µg, and 20 µg) demonstrated 
significantly greater AUC h.pg/mL values for the 20 µg group 
compared with all other treatment groups (Table 1).
At doses of 5–20 µg, both the once-daily and twice-daily 
lixisenatide treatment regimens were associated with statisti-
cally significant improvements in the primary endpoint of 
change in the AUC for postprandial blood glucose after a 
standardized test meal on day 28. The greatest reductions in 
postprandial blood glucose compared with placebo were seen 
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after the breakfast test meal; there were no significant dif-
ferences between the two treatment regimens in the primary 
endpoint. As observed with other GLP-1 peptide agonists, 
five patients did form antibodies to lixisenatide, and pharma-
cokinetic data were reported only for those individuals who 
were antibody-negative (n = 59) due to a potential interaction 
between anti-lixisenatide antibodies and the assay to deter-
mine lixisenatide plasma concentrations. In this study, the 
half-life of lixisenatide was 2.7–4.3 hours and was slightly 
longer in the groups that received twice-daily dosing.
In a two-way crossover study, 22 patients with type 2 
diabetes were randomized to a single subcutaneous injec-
tion of lixisenatide 20 µg or placebo.18 Two hours after 
the lixisenatide or placebo injection, patients received an 
intravenous bolus of glucose 0.3 g/kg body weight over a 
period of 30 seconds. Lixisenatide enhanced the  first-phase 
insulin response to intravenous glucose by more than 
 six-fold and second-phase insulin response by approximately 
three-fold compared with placebo (Figure 2). In this study, 
lixisenatide did not affect glucagon suppression. Maximum 
plasma concentrations were achieved 2 hours after the 
single injection.
To determine the pharmacokinetics and safety of 
l ixisenatide in patients with renal impairment, a single 
5 µg  subcutaneous injection was administered to eight 
healthy subjects with normal renal function (creatinine 
 clearance .80 mL/minute), and eight each with mild 
(50–80 mL/minute), moderate (30–50 mL/minute), or 
severe renal impairment (,30 mL/minute, but not requiring 
dialysis).19 AUC and C
max
 values observed in patients with 
mild to moderate renal impairment did not differ significantly 
from those observed in healthy subjects. In patients with 
severe renal impairment, drug exposure was increased, 
suggesting that dosage adjustment may be required.
To characterize the dose-response effect of lixisenatide 
fully, a total of eight regimens (5, 10, 20, or 30 µg) each 
administered once daily or twice daily, were compared with 
placebo in a 13-week, randomized, placebo-controlled, 
parallel-group study of 542 patients with type 2 diabetes 
(HbA
1c
 $7.0% to ,9.0%) who were inadequately controlled 
on metformin monotherapy.20 The lixisenatide 20 µg and 
30 µg doses were administered in escalating doses during the 
first 4 weeks of the study, with the dose initiated at 10 µg for 
1 week and increased by 5 µg per week up to the target dose. 
At week 13, statistically significant reductions in the primary 
endpoint (change in HbA
1c
 from baseline to endpoint) were 
observed for all lixisenatide treatment groups compared 
with placebo (all P , 0.01 versus  placebo). A dose-response 
relationship for HbA
1c
 level was observed for both the once-
daily and twice-daily lixisenatide  dosing regimens. Mean 
HbA
1c
 reductions from the mildly hyperglycemic baseline 
HbA
1c
 of 7.6% were 0.47%, 0.50%, 0.69%, and 0.76% for 
the once-daily lixisenatide regimens, and 0.65%, 0.78%, 
0.75% and 0.87% for the twice-daily regimens, respectively, 
compared with 0.18% for placebo (Figure 3). A target 
Table 1 Pharmacokinetic results from a study of 64 patients with type 2 diabetes randomized to lixisenatide once-daily or twice-daily, 
or placebo for 28 days. Results are for the 24-hour measurement period performed on days 4, 12, and 2817
Variable Day 4 (5 μg) Day 12 (10 μg) Day 28 (20 μg)
Lixisenatide  
1×/day (n = 8)
Lixisenatide  
2×/day (n = 11)
Lixisenatide  
1×/day (n = 9)
Lixisenatide  
2×/day (n = 11)
Lixisenatide  
1×/day (n = 9)
Lixisenatide  
2×/day (n = 11)
AUC h⋅pg/mL  
(mean ± SD)
267.6 ± 130 512.6 ± 152 420.5 ± 178 916.0 ± 249 847.8 ± 337 1788.6 ± 709
Cmax, pg/mL  
(mean ± SD)
37.3 ± 12 50.9 ± 17 82.7 ± 37 108.6 ± 24 187.2 ± 70 234.4 ± 90
tmax, h (median) 1.25 2.25 1.25 2.25 1.25 1.25
T½, h (median) 3.4 4.3 2.7 3.1 2.8 3.2
Abbreviations: AUC, area under the concentration-time curve; SD, standard deviation; tmax, time to peak plasma concentration; t1/2, elimination half-life.
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Figure 2 Mean insulin secretion rate after an intravenous glucose challenge following 
injection of lixisenatide 20 µg or placebo.18
Note: Data compiled from ClinicalTrials.gov.
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HbA
1c 
of ,7.0% at study end was achieved in 68% of patients 
receiving lixisenatide 20 µg and 30 µg once daily compared 
with 32% of patients receiving placebo (P , 0.0001). 
Statistically significant dose-dependent reductions from 
baseline in fasting and 2-hour postprandial plasma glucose 
were also observed. The improvements in glycemic control 
with lixisenatide were coupled with reductions in body 
weight, ie, 3.0 kg for lixisenatide 20 µg compared with 
1.9 kg for placebo (Figure 4). In this study, the once-daily 
and twice-daily regimens provided similar levels of efficacy, 
and doubling the daily dose in the twice-daily regimens did 
not provide relevant additional improvements in glycemic 
control over the once-daily regimens.
Lixisenatide has also been investigated in a 4-week trial 
in 150 patients with type 2 diabetes not achieving adequate 
glycemic control with metformin, using liraglutide as the 
active comparator. The primary endpoint was change from 
baseline in postprandial plasma glucose after a standardized 
breakfast. Although the trial has been completed, results have 
not yet been presented.
Efficacy studies: the GETGOAL 
program
The Phase III clinical trial program for lixisenatide began in 
2008. Known as the GETGOAL program, it consisted of two 
parallel programs. The most advanced involved ten individual 
clinical trials to assess the efficacy and safety of lixisenatide 
in adult patients with type 2 diabetes treated with various oral 
antidiabetes agents or insulin. The program enrolled more 
than 4500 patients globally, the first results of which were 
presented in abstract form in 2010 (Table 2). The remaining 
trials are expected to complete in 2011. The second part 
of the program involved a combination of lixisenatide and 
the once-daily, long-acting insulin analog, insulin glargine. 
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Abbreviations: HbA1c, glycosylated hemoglobin; LS, least squares.
Note: Reproduced from Becker RH, Ruus P, Liu Y-H, Kapitza C. Restoration of insulin release with lixisenatide in patients with type 2 diabetes. Diabetologica. 2010;53 
Suppl 1:S339, with permission of the publisher.
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Table 2 Summary of the GETGOAL Phase iii clinical trial program with lixisenatide
Trial Comparator Participants Duration  
(weeks)
Primary  
outcome
Secondary  
outcome
Status
GETGOAL- 
Mono
Lixisenatide vs PCB  
(1-step and 2-step  
titration)
361 adults previously  
untreated with  
antidiabetes agents
12 Change in HbA1c  
from baseline
Changes in body  
weight, FPG,  
2 hour-PPG
Completed
GETGOAL-F1 Lixisenatide + MET vs  
PCB + MET (1-step  
and 2-step titration)
450 adults previously  
treated with MET
24 Change in HbA1c  
from baseline
Changes in body  
weight, FPG
Completed
GETGOAL-S Lixisenatide + SU  
vs PCB + SU
859 adults previously  
treated with SU
24 Change in HbA1c  
from baseline
Changes in body weight,  
FPG, 2 hour-PPG
Completed
GETGOAL-L Lixisenatide + basal  
insulin vs PCB + basal  
insulin
495 adults previously  
treated with basal  
insulin
24 Change in HbA1c  
from baseline
Changes in body weight,  
FPG, change from  
baseline in insulin doses
Completed
GETGOAL-P Lixisenatide + PiO vs  
PCB + PiO
450 adults previously  
treated with PiO
24 Change in HbA1c  
from baseline
Changes in body  
weight, FPG, fasting  
plasma insulin
Expected  
completion 
Q2 2011
GETGOAL-X Lixisenatide + MET vs  
EXE + MET
634 adults previously  
treated with MET
24 Noninferiority in  
HbA1c reduction  
from baseline
Changes in body weight,  
FPG, quality of life
Completed
GETGOAL-M Lixisenatide (morning  
or evening dose) +  
MET vs PCB + MET
680 adults previously  
treated with MET
24 Change in HbA1c  
from baseline
Changes in body weight,  
FPG, 2 hour-PPG
Completed
GETGOAL- 
Mono JAPAN  
LTS
Open-label lixisenatide  
(1- and 2-step titration)
66 adults not treated  
with antidiabetes  
agents
52 Safety measures Changes in HbA1c  
and FPG from baseline
Completed
GETGOAL- 
L-ASiA
Lixisenatide + basal  
insulin vs PCB +  
basal insulin
311 adults previously  
treated with basal  
insulin ± SU
24 Change in HbA1c  
from baseline
Change from baseline  
in body weight, FPG,  
insulin doses
Completed
GETGOAL- 
M-As China
Lixisenatide + MET ±  
SU vs PCB + MET ± SU
380 adults previously 
treated with MET or 
MET + SU
24 Change in HbA1c  
from baseline
Changes in body weight,  
FPG, 2 hour-PPG
Ongoing
Notes: All the 24-week GETGOAL trials with the exception of GETGOAL-L-ASiA have a variable extension period; the GETGOAL-Mono JAPAN LTS trial has a 24-week 
extension period. Data sourced from the ClinicalTrials.gov website (http://clinicaltrials.gov/).
Abbreviations: EXE, exenatide; MET, metformin; PCB, placebo; PiO, pioglitazone; SU, sulfonylurea; FPG, fasting plasma glucose; PPG, postprandial glucose.
For all these trials, the once-daily lixisenatide 20 µg dose 
was selected, because in previous trials it had demonstrated 
the best efficacy to tolerability ratio.
GETGOAL-Mono
The first results to be reported were those of the GETGOAL-
Mono trial. In this 12-week trial, 361 patients with type 2 
diabetes (HbA
1c
 7%−10%) not currently receiving anti diabetes 
agents were randomized to one of four once-daily treatment 
regimens, ie, 119 patients underwent a one-step titration with 
lixisenatide (10 µg for 2 weeks then 20 µg), 120 underwent a 
two-step titration with lixisenatide (10 µg for 1 week, 15 µg 
for 1 week then 20 µg), 61 underwent a one-step placebo 
titration, and 61 underwent a two-step placebo titration.21 The 
mean age of patients was 54 years and the mean duration of 
type 2 diabetes was 2.5 years. Both lixisenatide titration groups 
were associated with statistically significant improvements 
in HbA
1c
 compared with placebo (P , 0.0001, Table 3). In 
addition, more patients in the lixisenatide groups achieved 
HbA
1c
 #6.5% (25.4% one-step titration, 31.9% two-step 
titration) and ,7.0% (46.5% one-step titration, 52.2% two-step 
titration) compared with placebo (26.8% and 12.5%, respec-
tively; P , 0.01). Lixisenatide was associated with significant 
improvements in both 2-hour postprandial and fasting plasma 
glucose compared with placebo, with a particularly pronounced 
effect on postprandial plasma glucose (Table 3). Decreases in 
body weight were observed in all groups.
GETGOAL-X
Results from several other GETGOAL studies have been 
unveiled by Sanofi-Aventis and Zealand Pharma and presented 
in abstract form at conferences in 2011. GETGOAL-X was the 
first head-to-head trial comparing lixisenatide with another 
GLP-1 agonist. In this randomized, open-label, 24-week 
trial, once-daily lixisenatide 20 µg was compared with twice-
daily exenatide 10 µg as add-on therapy in 634 people not 
achieving glycemic control with metformin $1.5 g/day.22 
Both groups received a stepwise increase in dose, up to a 
maximum daily dose of 20 µg. The mean age of the patients 
was 57 years, mean duration of type 2 diabetes was 7 years, 
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and mean baseline HbA
1c
 was 8.0%. Lixisenatide achieved 
its primary endpoint of noninferiority in HbA
1c
 reduction 
from baseline compared with exenatide using a predefined 
upper limit of 95% confidence interval (CI) #0.4: least 
squares mean difference = 0.17 (95% CI 0.03–0.30, Table 4). 
Improvements in mean fasting plasma glucose and the per-
centage of patients achieving HbA
1c
 ,7.0% were comparable 
between groups (Table 4). Mean body weight significantly 
decreased from baseline, ie, 94.5 kg to 91.7 kg with lixisen-
atide and 96.7 kg to 92.9 kg with exenatide. Participants in 
this trial are also being followed in a variable extension of 
at least 52 weeks.
GETGOAL-S
GETGOAL-S was the largest trial in the clinical program and 
investigated the efficacy and safety of lixisenatide as add-on 
Table 4 Preliminary results from the GETGOAL-X trial, a head-to-head comparison of lixisenatide and exenatide in patients not 
achieving adequate glycemic control with metformin $1.5 g/day22
Parameter Lixisenatide Exenatide
Mean baseline and 24-week changes in efficacy  
parameters (iTT population)
n = 311 n = 305 LS mean difference 
(95% Ci)
 HbA1c (%) Baseline ± SD 7.97 ± 0.82 7.96 ± 0.77 0.17 (0.03 to 0.30)
LS mean ± SE change from baseline −0.79 ± 0.05 −0.96 ± 0.05
 FPG (mg/dL) Baseline ± SD 175 ± 37 174 ± 41 4.1 (−0.9 to 9.4)
LS mean ± SE change from baseline −22.0 ± 2.1 −26.1 ± 2.1
 Body weight (kg) Baseline ± SD 94.5 ± 19.4 96.7 ± 22.8 1.02 (0.46 to 1.58)
LS mean ± SE change from baseline −2.96 ± 0.23 −3.98 ± 0.23
Safety parameters (safety population) n = 318 n = 316 P value
n (%) patients with symptomatic hypoglycemia* 8 (2.5%) 25 (7.9%) ,0.05
n hypoglycemic events 8 48
n (%) patients with nausea 78 (24.5%) 111 (35.1%) ,0.05
n (%) patients with diarrhea 33 (10.4%) 42 (13.3%) NS
n (%) patients with vomiting 32 (10.1%) 42 (13.3%) NS
Note: *Event with clinical symptoms with either plasma glucose , 60 mg/dL (3.3 mmol/L) or prompt recovery after oral carbohydrate administration if no plasma glucose 
measurement was available.
Abbreviations: CI, confidence interval; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; ITT, intent-to-treat; LS, least squares; NS, not significant; SD, standard 
deviation; SE, standard error of the mean.
Table 3 Mean baseline and 12-week changes in glycemic efficacy variables for 361 patients with type 2 diabetes randomized to one of four 
once-daily treatment regimens, ie, lixisenatide two-step titration (10 µg for 1 week, 15 µg for 1 week then 20 µg; n = 120), lixisenatide 
one-step titration (10 µg for 2 weeks then 20 µg; n = 119), placebo two-step titration (n = 61), or placebo one-step titration (n = 61)21
Variable Placebo (n = 121) Lixisenatide
2-step titration (n = 120) 1-step titration (n = 118)
HbA1c (%) Baseline 8.07 ± 0.92 7.97 ± 0.91 8.06 ± 0.85
Change from baseline –0.19 ± 0.12 –0.73 ± 0.12 –0.85 ± 0.12
LS mean difference vs PCB − −0.54 ± 0.12 −0.66 ± 0.12
95% Ci − (−0.79 to −0.30) (−0.90 to −0.42)
2-hour PPG  
(mmol/L)*
Baseline 13.99 ± 4.78 14.67 ± 3.78 14.55 ± 3.36
Change from baseline –0.65 ± 0.56 –4.51 ± 0.57 –5.47 ± 0.55
LS mean difference vs PCB − –3.86 ± 0.77 –4.82 ± 0.74
95% Ci − (–5.38 to –2.35) (–6.29 to –3.36)
Glucose excursion  
(mmol/L)*
Baseline 4.72 ± 3.65 5.45 ± 3.02 5.25 ± 2.89
Change from baseline –0.67 ± 0.45 –3.77 ± 0.45 –4.36 ± 0.44
LS mean difference vs PCB − –3.10 ± 0.61 –3.69 ± 0.59
95% Ci − (–4.30 to –1.90) (–4.85 to –2.53)
FPG (mmol/L) Baseline 8.91 ± 2.17 9.17 ± 1.98 9.02 ± 1.97
Change from baseline +0.19 ± 0.26 –0.68 ± 0.25 –0.89 ± 0.25
LS mean difference vs PCB − –0.87 ± 0.26 –1.08 ± 0.26
95% Ci − (–1.37 to −0.36) (–1.59 to –0.58)
Notes: *At selected sites (n = 62, 60, and 65 for the placebo, lixisenatide 2-step, and lixisenatide 1-step groups, respectively); baseline data are mean ± standard deviation; 
change from baseline (to week 12 or last observation carried forward) data are LS mean ± standard error of the mean.
Abbreviations: CI, confidence interval; FPG, fasting plasma glucose; LS, least squares; PCB, placebo; PPG, postprandial plasma glucose.
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therapy in patients not achieving glycemic control with a 
sulfonylurea, with or without metformin. GETGOAL-S was 
a randomized, double-blind, placebo-controlled study with a 
24-week treatment period.23 In total, 859 patients were ran-
domized to receive either lixisenatide or placebo in stepwise 
increasing doses, up to a maintenance dose of 20 µg daily. 
The trial results have not yet been presented in abstract form, 
but a Sanofi-Aventis press release has reported that patients 
in the lixisenatide group experienced a significant reduction 
in HbA
1c
 levels, with a −0.74% difference versus placebo 
(P , 0.0001) at week 24. The drug was also associated with 
significant reductions in 2-hour postprandial (P , 0.0001) 
and fasting plasma glucose levels (P , 0.0001). Body weight 
was also significantly reduced (P , 0.0001) compared with 
patients receiving placebo.
Combined lixisenatide and insulin
In patients with type 2 diabetes, the progressive decline in 
beta cell function and increasing insulin resistance com-
bined with an increased hepatic glucose output as a result 
of hypersecretion of glucagon leads to elevations in both 
fasting and postprandial glucose levels. Therefore, there is 
significant merit in the use of combination therapies to target 
these multiple pathophysiological defects. This has drawn 
attention to the possibility of using GLP-1 receptor agonists 
with basal insulin, the former agent targeting postprandial 
plasma glucose and the latter agent targeting fasting plasma 
glucose. Two trials in the GETGOAL program are evaluat-
ing this rationale.
GETGOAL-L-ASiA
GETGOAL-L-ASIA was the first study to evaluate lixisen-
atide in combination with a basal insulin. This 24-week, 
 double-blind, placebo-controlled trial assessed the efficacy 
and safety of lixisenatide as add-on therapy in 311 Asian 
patients with type 2 diabetes not achieving glycemic 
control with basal insulin (with or without a sulfonylurea).24 
Patients in the trial had a mean type 2 diabetes duration 
of 14 years, mean age of 58 years, body mass index of 
25.3 kg/m2, and a mean baseline HbA
1c
 of 8.53%. Patients 
were randomized to add either lixisenatide 20 µg once daily 
(n = 154) or placebo (n = 157) to their existing treatment 
regimen; approximately 60% of patients were taking insulin 
glargine as their basal insulin. The primary endpoint was 
change in HbA
1c
 from baseline to week 24. Results from 
the trial showed that lixisenatide once daily in combination 
with basal insulin significantly improved glycemic control, 
the addition of lixisenatide to basal insulin reducing HbA
1c
 
levels by 0.9% versus placebo (P , 0.0001). Patients 
receiving lixisenatide were more likely to achieve an HbA
1c
 
#6.5% and ,7.0%: 17.8% and 35.6% for lixisenatide, 
respectively, compared with 1.3% and 5.2%, respectively, for 
placebo (P , 0.0001). Lixisenatide was also associated with 
significantly greater improvements in 2-hour postprandial 
plasma glucose.
GETGOAL-L
The second trial to investigate the benefits of lixisenatide in 
combination with basal insulin was GETGOAL-L, which 
randomized 495 patients not achieving adequate glycemic 
control on a combination of insulin glargine and metformin 
to add-on lixisenatide 20 µg once daily or placebo for 24 
weeks.25 In the lixisenatide-basal insulin combination trials, 
the first step after screening was to optimize insulin therapy 
to the point where the patient was not achieving any further 
reductions in HbA
1c
 or where hypoglycemia became the 
limiting factor. The patients were then randomized to one 
of the two treatment arms while continuing with maximally 
optimized glargine therapy for a further 6 months, with both 
lixisenatide and insulin glargine injected in the morning 
within 1 hour prior to breakfast. The results are expected to 
be presented at a medical congress in 2011, but a Sanofi-
Aventis press release has reported that the GETGOAL-L trial 
showed a significant reduction in HbA
1c
 levels (P = 0.0002) 
with lixisenatide, without a significant increase in the 
incidence of symptomatic hypoglycemia (P = 0.14) ver-
sus placebo. In addition, patients treated with lixisenatide 
had significantly improved postprandial plasma glucose 
after a test meal (P , 0.0001) and a significant reduction 
in body weight (P , 0.0001). These results confirm those 
of GETGOAL-L-Asia, this time in a broader population 
including both Caucasian and Asian patients.
Additional clinical efficacy trials
Lixisenatide versus sitagliptin
In addition to the GETGOAL program, two other Phase III 
trials with lixisenatide were listed on the ClinicalTrials.gov 
registry. The first was a 24-week Phase III study compar-
ing lixisenatide with sitagliptin as add-on therapy in 300 
adults younger than 50 years of age, with a body mass index 
$30 kg/m2 and not achieving adequate glycemic control 
with metformin. The primary outcome in this double-blind, 
double-dummy trial was the percentage of patients with 
HbA
1c
 values ,7% and a weight loss of at least 5% of base-
line body weight. The trial has been completed, but results 
not yet presented.
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Cardiovascular outcome trial
The second Phase III trial was ELIXA (Evaluation of 
 Cardiovascular Outcomes in Patients With Type 2 Diabetes 
After Acute Coronary Syndrome During Treatment With 
AVE0010 [lixisenatide]). This large cardiovascular out-
come trial recruited patients with type 2 diabetes who had 
experienced an acute coronary syndrome event (ie, ST 
segment elevation myocardial infarction, non-ST segment 
elevation myocardial infarction, or unstable angina) with 
a target sample size of 6000. Patients were randomized to 
once-daily lixisenatide or placebo, with a median estimated 
follow-up period of approximately 2 years. The primary 
endpoint was time to the first occurrence of a primary 
cardiovascular event, ie, cardiovascular death, nonfatal 
myocardial infarction, nonfatal stroke, and hospitalization 
for unstable angina. This trial meets the new US Food and 
Drug Administration guidance introduced in 2008, which 
requires that manufacturers developing new drugs for type 2 
diabetes provide evidence that the therapy will not increase 
the risk of cardiovascular events. Results from this trial are 
not expected until 2013.
Safety and tolerability
As a result of the lack of published data, safety and toler-
ability information on lixisenatide is currently limited, but 
the following information provides a summary of the pub-
lished findings.
Treatment-emergent adverse events
In the GETGOAL-Mono trial there was only one (0.4%) seri-
ous treatment-emergent adverse event in a  lixisenatide-treated 
patient (two-step titration group) compared with five (4.1%) 
in the placebo group.21 Nine patients discontinued due to 
a treatment-emergent adverse event, ie, five (4.2%) in the 
lixisenatide two-step group, three (2.5%) in the lixisenatide 
one-step group, and one (0.8%) in the placebo group.
In the GETGOAL-X trial, the proportion of patients 
with adverse events was generally comparable between the 
lixisenatide and exenatide groups.22 There were 33 (10.4%) 
patient discontinuations due to adverse events (mainly gas-
trointestinal) in the lixisenatide group and 41 (13.0%) with 
exenatide. A greater proportion of patients in the lixisenatide 
group tolerated the target dose of 20 µg/day (93% versus 
83% with exenatide).
In GETGOAL-L-ASIA, 86% of patients on lixisenatide 
completed the trial compared with 92% of placebo patients.24 
Serious treatment-emergent adverse events occurred in 
10 (6.5%) lixisenatide patients and nine (5.7%) placebo 
patients. Fourteen (9.1%) patients in the lixisenatide group 
discontinued due to adverse events compared with five 
(3.2%) in the placebo group, mostly due to gastrointestinal 
events.
Gastrointestinal adverse events
The most frequent adverse events associated with lixisen-
atide include transient dose-dependent nausea, diarrhea, and 
vomiting.20–22,24 In the GETGOAL-Mono trial, nausea was the 
most frequent (24.2% for lixisenatide two-step, 20.2% for lix-
isenatide one-step, 4.1% for placebo).21 In the GETGOAL-X 
trial, overall gastrointestinal tolerability appeared better for 
lixisenatide versus exenatide, with fewer cases of nausea and 
vomiting (Table 4).22 In GETGOAL-L-ASIA, nausea and 
vomiting were reported in 39.6% and 18.2% of the patients, 
respectively, in the lixisenatide group and 4.5% and 1.9% of 
patients, respectively, in the placebo group.24
Hypoglycemia
Similar to other GLP-1 agonists, lixisenatide only stimulates 
insulin secretion and suppresses glucagon secretion in the 
presence of elevated blood glucose and, as a result, the risk 
of hypoglycemia should be reduced compared with some 
other antidiabetes therapies. In the GETGOAL-Mono trial, 
symptomatic hypoglycemia occurred in three patients (2.5%) 
in the lixisenatide two-step group, one (0.8%) in the lixisen-
atide one-step group, and two (1.6%) in the placebo group, 
with no cases of severe hypoglycemia.21 In GETGOAL-X, 
initial results showed that significantly fewer people with type 
2 diabetes treated with lixisenatide reported symptomatic 
hypoglycemia versus patients treated with exenatide, ie, eight 
(2.5%) versus 25 (7.9%), respectively; P , 0.05 (Table 4).22 A 
total of eight hypoglycemic events were reported in patients 
receiving lixisenatide compared with 48 events in patients 
receiving exenatide. No severe episodes were reported. 
With other GLP-1 agonists, the highest incidence of hypo-
glycemic events has been observed when they are used in 
combination with a sulfonylurea. Preliminary results from the 
GETGOAL-S trial report that lixisenatide as add-on therapy 
to a sulfonylurea did not significantly increase the risk of 
symptomatic hypoglycemia compared with placebo.23 In the 
GETGOAL-L-ASIA trial, 42.9% of patients in the lixisen-
atide group reported symptomatic hypoglycemia compared 
with 23.6% in the placebo group.24 However, in patients 
not receiving a sulfonylurea, the addition of lixisenatide to 
a basal insulin resulted in a hypoglycemia rate of 31.8% in 
lixisenatide patients and 28.3% in placebo patients. There 
were no cases of severe hypoglycemia.
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Antibody formation
Antibody formation occurs in a significant number of patients 
treated with GLP-1 receptor agonists.26 It is possible that 
exendin-4-based compounds, which include exenatide and 
lixisenatide, may result in greater antibody formation, possibly 
because of a lower homology with native GLP-1. However, only 
one study to date has reported antibody data with lixisenatide, 
and the relevance of antibody formation remains unclear.
Discussion
The clinical effectiveness of lixisenatide has been evaluated 
in the GETGOAL program. This was designed to assess the 
efficacy and safety of lixisenatide across the spectrum of type 
2 diabetes care, both as monotherapy and in combination with 
commonly used antidiabetes agents, in a series of random-
ized, controlled trials in more than 4500 people (Table 2). The 
first Phase III results with lixisenatide have been presented 
and demonstrate that it exhibits the properties expected of a 
GLP-1 receptor agonist in terms of improving glycemic con-
trol while reducing or eliminating the risk of hypoglycemia 
and weight gain. If approved, lixisenatide would be the third 
GLP-1 receptor agonist to enter the market after exenatide 
and liraglutide, with which it would have to compete.
In a head-to-head trial, initial results showed noninferior 
HbA
1c
 reduction and weight loss with once-daily lixisenatide 
compared with twice-daily exenatide, whilst delivering a bet-
ter safety and tolerability profile.22 However, in the Liraglutide 
Effect and Action in Diabetes (LEAD)-6 trial, a head-to-head 
comparison of subcutaneous liraglutide 1.8 mg once daily 
and exenatide 10 µg twice daily, liraglutide was associated 
with a significantly greater reduction in HbA
1c
 compared with 
exenatide (1.12% versus 0.79%, respectively).27 It will not 
be known how lixisenatide compares with liraglutide until 
the results of the head-to-head trial with liraglutide become 
available. A key differentiating factor is likely to be the effect 
of lixisenatide on postprandial plasma glucose. Although 
liraglutide targets both fasting and postprandial plasma 
glucose, significantly greater reductions in fasting plasma 
glucose are achieved, reflecting the action of liraglutide as 
a 24-hour GLP-1 agonist. In contrast, lixisenatide achieves 
greater reductions in postprandial plasma glucose as a result 
of its more rapid time-action profile, while maintaining the 
ability to be dosed once daily. 
The dosing regime is an important consideration for any 
new GLP-1 receptor agonist. With lixisenatide, dose-response 
relationships were demonstrated for both the once-daily 
and twice-daily regimens, with similar efficacy levels.20 The 
once-daily 20 µg dose of lixisenatide demonstrated the best 
efficacy-to-tolerability ratio and was selected for the GET-
GOAL program. The convenience of a once-daily dosing 
regimen is likely to be preferred by patients and would allow 
lixisenatide to compete with both twice-daily exenatide and 
once-daily liraglutide.
An important factor in the appeal of liraglutide and 
exenatide is the weight loss seen in many patients, and 
lixisenatide seems to produce similar results. The recent 
release of preliminary GETGOAL-S results, although not 
yet published in abstract form, indicate that lixisenatide as 
add-on to a sulfonylurea was associated with a significant 
decrease in body weight (P , 0.0001) compared with patients 
receiving placebo as add-on to a sulfonylurea.23
A pronounced effect of lixisenatide on postprandial 
plasma glucose in addition to a tendency for weight loss has 
led to investigation of the combined effects of lixisenatide and 
long-acting insulins in patients with type 2 diabetes. There is 
a good rationale for such a combination, with one targeting 
postprandial and the other fasting plasma glucose, providing 
additive effects on HbA
1c
, and one associated with weight 
loss and the other with a degree of weight gain. In addition, 
both GLP-1 receptor agonists and insulin analogs, such as 
insulin glargine, exhibit a protective function on beta cells, 
suggesting that the two agents in combination might represent 
a new therapeutic option for preservation of beta cell mass in 
patients with type 2 diabetes. Recent results with exenatide 
have demonstrated the feasibility of such an approach. In a 
30-week study, 261 adults with type 2 diabetes who were 
receiving insulin glargine alone or in  combination with 
metformin and/or pioglitazone were randomized to exenatide 
or placebo while continuing to optimize their insulin treat-
ment.28 Patients had an average type 2 diabetes duration 
of 12 years, mean HbA
1c
 8.3%–8.5%, and were receiving 
an average insulin dose of 47–50 U/day. At the end of the 
study, mean HbA
1c
 had decreased by 1.74% with exenatide 
and 1.04% with placebo (between-group  difference, −0.69% 
[95% CI, −0.93% to −0.46%]; P , 0.001). The exenatide 
treatment group also experienced other benefits, including a 
weight decrease of 1.8 kg compared with a weight increase 
of 1.0 kg with placebo, and an average increase in insulin 
dose of 13 U/day with exenatide compared with 20 U/day 
for placebo. The estimated rate of minor hypoglycemia was 
similar between the groups.
The findings confirm the rationale for combining the 
complementary effects of a GLP-1 receptor agonist with a 
basal insulin and have paved the way for similar trials with 
lixisenatide. In addition, preclinical studies have shown that 
beta cells treated with a combination of lixisenatide and 
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insulin glargine are protected against cytokine-induced and 
free fatty acid-induced apoptosis, with additive benefits for 
the two agents in combination compared with either alone.16 
The findings suggest that a combination of a GLP-1 recep-
tor agonist and insulin glargine might represent an effective 
strategy for preserving beta cell mass in patients with type 
2 diabetes and potentially could alter disease progression. 
Phase III clinical trials for the lixisenatide and insulin glargine 
combination have been completed, with preliminary results 
showing an approximately 0.9% reduction in HbA
1c
 on top 
of basal insulin.24,25
The currently available data show that lixisenatide is 
well tolerated. The GLP-1 receptor represents an established 
therapeutic target in type 2 diabetes, with agonists of 
this receptor demonstrating improved glucose tolerance 
alongside a low risk of hypoglycemia, beneficial weight 
loss, and the potential to modify disease progression. Early 
results with lixisenatide look promising, but data from the 
GETGOAL program are only just beginning to appear, 
and before any firm conclusions can be made, must be 
published in peer-reviewed journals. If results are posi-
tive, lixisenatide will be the third GLP-1 receptor agonist 
to enter the market. The factor that may distinguish it from 
exenatide and liraglutide is its strong postprandial effect. 
This property may prove beneficial in patients with mildly 
elevated HbA
1c
, in whom a therapeutic response is difficult 
to achieve with many existing antidiabetes therapies, as 
well as for use in combination with a basal insulin, such 
as insulin glargine, to achieve better glycemic control and 
minimize weight gain.
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